While the clinical portion of this study is inherently limited due to the inclusion of only one patient, these results highlight the potential efficacy of RET inhibition, and the need for increased surveillance of RET alterations in breast cancer primary tumors and recurrences. This evidence concerns the gene RET and breast carcinoma.